CAS No. : 1431303-72-8
(Synonyms: ORY-1001 (dihydrochloride); RG6016 (dihydrochloride); RO 7051790 (dihydrochloride))
| Size | Price | Stock |
|---|---|---|
| 5mg | $110 | In-stock |
| 10mg | $180 | In-stock |
| 25mg | $420 | In-stock |
| 50mg | $700 | In-stock |
| 100mg | $1200 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-12782T |
| M.Wt: | 303.27 |
| Formula: | C15H24Cl2N2 |
| Purity: | >98 % |
| Solubility: | H2O : 57.75 mg/mL (ultrasonic;warming);DMSO : 0.69 mg/mL (ultrasonic;warming) |
Iadademstat (ORY-1001) dihydrochloride is a selective irreversible lysine (K)-specific demethylase 1A (KDM1A/LSD1) inhibitor. IC50 & Target:KDM1A/LSD1[1] In Vitro:Iadademstat dihydrochloride is a KDM1A inhibitor that inactivate KDM1A by irreversible binding to the flavin adenine nucleotide (FAD) cofactor. Iadademstat has very high selectivity for KDM1A over the MAO enzymes, high selectivity over KDM1B and unrivaled subnanomolar cellular activity in differentiation and colony formation assays on mixed lineage leukemia (MLL)-translocated acute myeloid leukemia (AML) cell lines. Iadademstat provokes a time and dose-dependent induction of the Cd11b differentiation marker in MLL-AF9 cells, which interestingly preceeds changes in H3K4me2 levels. While MLL-translocated cells are especially sensitive, other acute leukemia (AL) cell lines also respond to Iadademstat[1]. In Vivo:Iadademstat reduces AML tumor growth in mice and rat xenografts and increases survival time in a disseminated model of T-ALL[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.